The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Open accessAbstract
Oncogenic activation of RAS genes via point mutations occurs in 20%–30% of human cancers. The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein. Functional studies have shown that the switch region of RAS interacts with a large number of effector proteins containing a common RAS-binding domain (RBD). Because RBD-mediated interactions are essential for RAS signaling, blocking RBD association with small molecules constitutes an attractive therapeutic approach. Here, we present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway. We also find that rigosertib binds to the RBDs of Ral-GDS and PI3Ks. These results suggest that targeting of RBDs across multiple signaling pathways by rigosertib may represent an effective strategy for inactivation of RAS signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
MOLMOL: A program for display and analysis of macromolecular structures
Koradi, R., Billeter, M., & Wüthrich, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00009-4 · Cited by 7,163
AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR
Laskowski, R., Rullmann, J. A., MacArthur, M., Kaptein, R., & Thornton, J. (1996) · Journal of Biomolecular NMR · doi:10.1007/bf00228148 · Cited by 5,502
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts
Shen, Y., Delaglio, F., Cornilescu, G., & Bax, A. (2009) · Journal of Biomolecular NMR · doi:10.1007/s10858-009-9333-z · Cited by 2,516
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Niesen, F. H., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,408
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction
Burgering, B. M. T., & Coffer, P. J. (1995) · Nature · doi:10.1038/376599a0 · Cited by 2,089
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“…Shimizu et al., 1983; Tabin et al., 1982; Taparowsky et al., 1983; Yuasa et al., 1983) and that these mutations occur in 20%–30% of human cancers, (Prior et al., 2012), spearheaded investiga- tions aimed at understanding the biochemical mechanisms that govern the function of these oncoproteins.”
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Reddy, E. P., Reynolds, R. K., Santos, E., & Barbacid, M. (1982) · Nature · doi:10.1038/300149a0 · Cited by 1,391
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Protein-binding assays in biological liquids using microscale thermophoresis
Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D., & Duhr, S. (2010) · Nature Communications · doi:10.1038/ncomms1093 · Cited by 1,138
Using NMRView to Visualize and Analyze the NMR Spectra of Macromolecules
Johnson, B. A. (2004) · Protein NMR Techniques · doi:10.1385/1-59259-809-9:313 · Cited by 1,027
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762
Nassar, N., Horn, G., Herrmann, C. A., Scherer, A., McCormick, F., & Wittinghofer, A. (1995) · Nature · doi:10.1038/375554a0 · Cited by 635
Refinement of protein structures in explicit solvent
Linge, J. P., Williams, M. A., Spronk, C. A. E. M., Bonvin, A. M. J. J., & Nilges, M. (2003) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10299 · Cited by 606
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Increasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
HADDOCK versus HADDOCK: New features and performance of HADDOCK2.0 on the CAPRI targets
de Vries, S. J., van Dijk, A. D. J., Krzeminski, M., van Dijk, M., Thureau, A., Hsu, V., Wassenaar, T., & Bonvin, A. M. J. J. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21723 · Cited by 556
Structure and activation of the human N-ras gene
Taparowsky, E., Shimizu, K., Goldfarb, M., & Wigler, M. (1983) · Cell · doi:10.1016/0092-8674(83)90390-2 · Cited by 527
Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Belle, P. A. V., Elder, D. E., & Herlyn, M. (2003) · PubMed · Cited by 445
ARIA: automated NOE assignment and NMR structure calculation
Linge, J. P., Habeck, M., Rieping, W., & Nilges, M. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.315 · Cited by 390
Yuasa, Y., Srivastava, S. K., Dunn, C. Y., Rhim, J. S., Reddy, E. P., & Aaronson, S. A. (1983) · Nature · doi:10.1038/303775a0 · Cited by 381
Self-citationStructure of the Ki-ras gene of the human lung carcinoma cell line Calu-1
Shimizu, K., Birnbaum, D., Ruley, M. A., Fasano, O., Suard, Y., Edlund, L., Taparowsky, E., Goldfarb, M., & Wigler, M. (1983) · Nature · doi:10.1038/304497a0 · Cited by 373
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Self-citationAllosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Hu, J., Stites, E. C., Yu, H., Germino, E. A., Meharena, H. S., Stork, P. J. S., Kornev, A. P., Taylor, S. S., & Shaw, A. S. (2013) · Cell · doi:10.1016/j.cell.2013.07.046 · Cited by 299
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.
Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Ritt, D. A., Monson, D. M., Specht, S. I., & Morrison, D. K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00569-09 · Cited by 238
Allosteric Effects of the Oncogenic RasQ61L Mutant on Raf-RBD
Fetics, S. K., Guterres, H., Kearney, B. M., Buhrman, G., Ma, B., Nussinov, R., & Mattos, C. (2015) · Structure · doi:10.1016/j.str.2014.12.017 · Cited by 229
Diaz, B., Barnard, D., Filson, A., MacDonald, S., King, A., & Marshall, M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4509 · Cited by 203
Recognizing and Defining True Ras Binding Domains I: Biochemical Analysis
Wohlgemuth, S., Kiel, C., Krämer, A., Serrano, L., Wittinghofer, F., & Herrmann, C. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.02.048 · Cited by 177
Paulson, J. R., & Taylor, S. S. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)65105-5 · Cited by 170
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P., Platzbecker, U., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00009-7 · Cited by 169
Tugarinov, V., Kay, L. E., Ibraghimov, I., & Orekhov, V. Y. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044032o · Cited by 164
Block, C., Janknecht, R., Herrmann, C., Nassar, N. N., & Wittinghofer, A. (1996) · Nature Structural Biology · doi:10.1038/nsb0396-244 · Cited by 150
Nucleotide Sequence Analysis of the T24 Human Bladder Carcinoma Oncogene
Reddy, E. P. (1983) · Science · doi:10.1126/science.6844927 · Cited by 129
Self-citationKiel, C., Wohlgemuth, S., Rousseau, F., Schymkowitz, J. W. H., Ferkinghoff‐Borg, J., Wittinghofer, F., & Serrano, L. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.02.046 · Cited by 102
Reddy, M. V. R., Venkatapuram, P., Mallireddigari, M. R., Pallela, V. R., Cosenza, S. C., Robell, K. A., Akula, B., Hoffman, B. S., & Reddy, E. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200570p · Cited by 97
Self-citationNonradioactive determination of Ras-GTP levels using activated ras interaction assay
Taylor, S. J., Resnick, R. J., & Shalloway, D. I. (2001) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(01)33067-7 · Cited by 92
RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling
McKay, M., Ritt, D. A., & Morrison, D. K. (2011) · Current Biology · doi:10.1016/j.cub.2011.02.033 · Cited by 77
A MEK-independent role for CRAF in mitosis and tumor progression
Mielgo, A., Seguin, L., Huang, M., Camargo, M. F., Anand, S., Franovic, A., Weis, S. M., Advani, S. J., Murphy, E. A., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2464 · Cited by 66
Terada, T., Ito, Y., Shirouzu, M., Tateno, M., Hashimoto, K., Kigawa, T., Ebisuzaki, T., Takio, K., Shibata, T., Yokoyama, S., et al. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2472 · Cited by 50
Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K)
Ito, Y., Hart, J. R., Ueno, L. A., & Vogt, P. K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420281111 · Cited by 40
Self-citationOussenko, I. A., Holland, J. F., Reddy, E. P., & Ohnuma, T. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1603 · Cited by 34
Self-citationFernandez, T. D. S., de Souza, J. M., Silva, M. L. M., et al. (1998) · Leukemia Research · doi:10.1016/s0145-2126(97)00112-4 · Cited by 32
Stephenson, J., He, L.-Z., & Mufti, G. J. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00056-t · Cited by 31
Cited by
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
“…in the case of MYC, mutagenesis studies have indicated that binding of a small molecule to disordered MYC is contained within a specific region of the MYC helix–loop–helix possible for us to exploit this biological process and develop small molecules that effectively block these interactions 37 .”
Self-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Metadata
- Authors
- Athuluri-Divakar, S. K., Vasquez-Del Carpio, R., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L., Hart, J. R., Vogt, P. K., Mulholland, D., Guha, C., Aggarwal, A. K., & Reddy, E. P.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 165
- Issue
- 3
- Pages
- 643-655
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2339828620
- Cited by
- 277
- References
- 52
- FWCI
- 18.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.